-
公开(公告)号：WO03094828A2
公开(公告)日：2003-11-20
申请号：PCT/CA0300679
申请日：2003-05-12
Applicant: INEX PHARMACEUTICALS CORP , TAM YING K , SEMPLE SEAN , KLIMUK SANDRA , CHIKH GHANIA
Inventor： TAM YING K , SEMPLE SEAN , KLIMUK SANDRA , CHIKH GHANIA
IPC: A61K48/00 , A61K39/00 , A61K39/39 , A61K47/18 , A61P31/00 , A61P31/04 , A61P35/00 , A61P37/00 , A61P37/02 , A61P37/04 , C12N15/09 , C12N15/117 , A61K
CPC classification number: C12N15/117 , A61K39/0011 , A61K39/39 , A61K2039/541 , A61K2039/55555 , A61K2039/55561 , C12N2310/315 , C12N2310/3341
Abstract: The invention discloses cancer vaccines comprising lipid-nucleic acid formulations in combination with one or more tumor-associated antigens which are capable of stimulating strong, Th-1 biased cellular immune responses to said tumor-associated antigens in vivo. It is further disclosed the subject cancer vaccines provide therapeutic efficacy in treating tumors in an animal.
Abstract translation: 本发明公开了包含脂质 - 核酸制剂与一种或多种肿瘤相关抗原组合的癌症疫苗，其能够在体内刺激对所述肿瘤相关抗原的强烈的Th-1偏向细胞免疫应答。 进一步公开了本发明的癌症疫苗在治疗动物中的肿瘤方面提供治疗功效。
-
公开(公告)号：WO0202078A3
公开(公告)日：2002-12-27
申请号：PCT/CA0100981
申请日：2001-06-29
Applicant: INEX PHARMACEUTICALS CORP , MADDEN THOMAS D , SEMPLE SEAN C
Inventor： MADDEN THOMAS D , SEMPLE SEAN C
IPC: A61K9/127 , A61K31/4745 , A61K31/475 , A61K45/06 , A61K47/24 , A61K47/28 , A61P35/00 , A61K31/47
CPC classification number: A61K9/127 , A61K9/1272 , A61K9/1278 , A61K31/4745 , A61K45/06 , A61K2300/00
Abstract: This invention relates to improved liposomal camptothecin compositions and methods of manufacturing and using such compositions for treating neoplasia and for inhibiting angiogenesis.
Abstract translation: 本发明涉及改进的脂质体喜树碱组合物以及制备和使用这些组合物治疗瘤形成和抑制血管生成的方法。
-
公开(公告)号：WO1995032706A1
公开(公告)日：1995-12-07
申请号：PCT/CA1995000321
申请日：1995-05-31
Applicant: INEX PHARMACEUTICALS CORP. , WILSCHUT, Jan, C. , SCHERRER, Peter , CHONN, Arcadio
Inventor： INEX PHARMACEUTICALS CORP.
IPC: A61K09/127
CPC classification number: A61K9/5184 , A61K9/1271 , C07K14/005 , C12N15/88 , C12N2740/16222
Abstract: Virosomes containing viral membrane fusion proteins and encapsulating therapeutic compounds are used to effectively deliver the therapeutic compounds to cytoplasm of mammalian host cells.
Abstract translation: 使用含有病毒膜融合蛋白和封装治疗化合物的病毒颗粒有效地将治疗化合物递送到哺乳动物宿主细胞的细胞质中。
-
4.发明申请
公开(公告)号：WO03039595A3
公开(公告)日：2003-09-18
申请号：PCT/CA0201717
申请日：2002-11-07
Applicant: INEX PHARMACEUTICALS CORP , SEMPLE SEAN , KLIMUK SANDRA , YUAN ZUAN-NING
Inventor： SEMPLE SEAN , KLIMUK SANDRA , YUAN ZUAN-NING
CPC classification number: C12N15/117 , A61K39/0011 , A61K39/39 , A61K2039/541 , A61K2039/55555 , A61K2039/55561 , C12N2310/315 , C12N2310/3341
Abstract: The present invention relates to compositions and methods for stimulating enhanced mucosal immune responses in vivo. Particularly, the present invention relates to lipid-nucleic acids ("LNA") formulations and methods of using thereof for stimulating enhanced mucosal immune responses in mammals. More particularly, the present invention relates to improved mucosal vaccines comprising target antigens associated with LNA formulations and methods of using thereof that stimulate antigen-specific mucosal immune responses in mammals.
Abstract translation: 本发明涉及用于在体内刺激增强的粘膜免疫应答的组合物和方法。 特别地，本发明涉及脂质 - 核酸（“LNA”）制剂及其用于刺激哺乳动物中增强的粘膜免疫应答的方法。 更具体地，本发明涉及包含与LNA制剂相关的靶抗原的改进的粘膜疫苗以及其在哺乳动物中刺激抗原特异性粘膜免疫应答的使用方法。
-
公开(公告)号：WO0234236A3
公开(公告)日：2003-01-09
申请号：PCT/CA0101513
申请日：2001-10-25
Applicant: UNIV BRITISH COLUMBIA , INEX PHARMACEUTICALS CORP , CULLIS PIETER R , MACLACHLAN IAN , FENSKE DAVID B
Inventor： CULLIS PIETER R , MACLACHLAN IAN , FENSKE DAVID B
IPC: A61K9/127 , A61K31/711 , A61K31/7115 , A61K47/18 , A61K47/24 , A61K47/26 , A61K47/34 , A61K48/00 , A61P9/10 , A61P11/00 , A61P17/06 , A61P19/02 , A61P29/00 , A61P35/00 , A61P37/08
CPC classification number: A61K9/1272
Abstract: The present invention provides lipid-based systemic delivery vehicles and method for selectively targeting an active agent to a specific tissue site. The methods include designing a lipid-based systemic delivery vehicle having a plurality of constitutent parts, and thereafter varying the amounts of each of the plurality of constituent parts to impart tissue selectivity. After tissue selectivity is imparted it is possible to selectively target an active agent to a specific tissue site.
Abstract translation: 本发明提供基于脂质的系统递送载体和用于将活性剂选择性靶向特定组织部位的方法。 所述方法包括设计具有多个构成部分的脂质系统递送载体，然后改变多个组成部分中的每一个以赋予组织选择性。 在赋予组织选择性之后，可以选择性地将活性剂靶向特定的组织部位。
-
Patent Agency Ranking
公开(公告)号：WO0236767A2
公开(公告)日：2002-05-10
申请号：PCT/CA0101540
申请日：2001-10-31
Applicant: INEX PHARMACEUTICALS CORP , MADDEN THOMAS D , WEBB MURRAY S
Inventor： MADDEN THOMAS D , WEBB MURRAY S
IPC: C12N15/09 , A61K9/00 , A61K9/19 , A61K31/7088 , A61K38/00 , A61K47/26 , A61K48/00 , A61P43/00 , C12N15/113 , C12N15/11 , A61K31/7125
CPC classification number: C12N15/113 , A61K9/0019 , A61K38/00 , A61K47/26 , C12N2310/315
Abstract: It has now been discovered that oligonucleotides which tend to form multimeric aggregates have greater toxicity in the aggregate form than in monomeric form. Thus, the present invention provides therapeutic oligonucleotide compositions of reduced in vivo toxicity, and a method for making such compositions, as well as a method for administration of the therapeutic oligonucleotide, where the therapeutic oligonucleotide in one that tends to form multimeric aggregates. Compositions containing such aggregate-forming oligonucleotides are treated by heating, preferably no more than 24 hours prior to administration, or using chemical species such as mannitol which disrupt aggregates.
Abstract translation: 现在已经发现，倾向于形成多聚体聚集体的寡核苷酸在聚集体形式中具有比单体形式更大的毒性。 因此，本发明提供了降低体内毒性的治疗性寡核苷酸组合物，以及制备该组合物的方法，以及治疗性寡核苷酸的施用方法，其中倾向于形成多聚体聚集体的治疗性寡核苷酸。 含有这种聚集形成寡核苷酸的组合物通过加热处理，优选不超过施用前24小时，或者使用破坏聚集体的化学物质例如甘露糖醇。
-
公开(公告)号：WO9955743A9
公开(公告)日：2000-10-05
申请号：PCT/US9909076
申请日：1999-04-27
Applicant: INEX PHARMACEUTICALS CORP , CHEN TAO , HE YUEHUA , CULLIS PETER , MADDEN THOMAS , SCHERRER PETER , KIM JUNG SOO , TIRRELL DAVID , JOSHI PHALGUN
Inventor： CHEN TAO , HE YUEHUA , CULLIS PETER , MADDEN THOMAS , SCHERRER PETER , KIM JUNG SOO , TIRRELL DAVID , JOSHI PHALGUN
CPC classification number: A61K9/1271 , C08F8/12 , C08F8/30 , C08F8/32 , C08F120/06 , C08F297/026
Abstract: The present invention relates generally to the amphiphilic polyelectrolyte, poly(2-ethylacrylic acid) and covalently bonded lipids to generate Lipo-PEAA. These Lipo-PEAA are then used to make pH-sensitive liposomes which become unstable, permeable or fusogenic with certain pH changes. In addition, this invention generally describes methods for delivering therapeutic compounds and drugs to target cells by administering to a host the pH-sensitive liposomes of the present invention.
Abstract translation: 本发明一般涉及两亲性聚电解质，聚（2-乙基丙烯酸）和共价键合的脂质以产生Lipo-PEAA。 然后将这些Lipo-PEAA用于制备pH敏感的脂质体，其在某些pH变化下变得不稳定，可渗透或融合。 此外，本发明通常描述了通过向宿主施用本发明的pH敏感性脂质体来将治疗化合物和药物递送至靶细胞的方法。
-
公开(公告)号：WO0003683A3
公开(公告)日：2000-04-27
申请号：PCT/US9916166
申请日：1999-07-16
Applicant: INEX PHARMACEUTICALS CORP , BOEY ANTHONY , CHEN TAO , LENG ESTHER , TARD PAUL G , WHEELER JEFFREY J , SCHERRER PETER , GRAHAM ROGER
Inventor： BOEY ANTHONY , CHEN TAO , LENG ESTHER , TARD PAUL G , WHEELER JEFFREY J , SCHERRER PETER , GRAHAM ROGER
CPC classification number: C12N15/88 , A61K9/1272 , A61K48/00
Abstract: This invention relates to liposomes which are useful for the introduction of nucleic acids into cells. The liposomes of the present invention entrap a condensing agent-nucleic acid complex and are suitable for nucleic acid-transfer delivery vehicles in clinical use. In addition, methods of transfecting a cell with a nucleic acid using the liposomes of the present invention are also disclosed.
Abstract translation: 本发明涉及用于将核酸引入细胞的脂质体。 本发明的脂质体包含缩合剂 - 核酸复合物并且适用于临床应用中的核酸转移递送载体。 另外，还公开了使用本发明的脂质体用核酸转染细胞的方法。
-
公开(公告)号：WO9954444A3
公开(公告)日：1999-12-09
申请号：PCT/CA9900372
申请日：1999-04-22
Applicant: INEX PHARMACEUTICALS CORP , BRITISH COLUMBIA CANCER AGENCY , JOSHI PHALGUN B , DURAND RALPH , GRAHAM ROGER W
Inventor： JOSHI PHALGUN B , DURAND RALPH , GRAHAM ROGER W
CPC classification number: A61K48/00 , A61K41/0038 , C12N13/00
Abstract: The present invention relates to methods for increasing the efficiency of transformation of cycling cells, the methods comprising synchronizing cells at a first stage of the cell cycle, and transforming the cells at a second stage of the cell cycle within about one cell cycle of the first stage with a genetically engineered nucleic acid that encodes a desired gene product. The invention further relates to cancer therapy and, in particular, to methods of efficiently transforming cancer cells with nucleic acids that encode gene products that inhibit the growth of cancer cells.
Abstract translation: 本发明涉及用于提高循环细胞转化效率的方法，所述方法包括在细胞周期的第一阶段同步细胞，以及在细胞周期的第二阶段，在第一个细胞的约一个细胞周期内转化细胞 具有编码所需基因产物的遗传工程化核酸的阶段。 本发明进一步涉及癌症治疗，尤其涉及用编码抑制癌细胞生长的基因产物的核酸有效转化癌细胞的方法。
-
公开(公告)号：WO9954445A2
公开(公告)日：1999-10-28
申请号：PCT/CA9900371
申请日：1999-04-22
Applicant: INEX PHARMACEUTICALS CORP , JOSHI PHALGUN B , MORTIMER IAN C , TAM PATRICK M S , MACLACHLAN IAN , GRAHAM ROGER W
Inventor： JOSHI PHALGUN B , MORTIMER IAN C , TAM PATRICK M S , MACLACHLAN IAN , GRAHAM ROGER W
IPC: C12N15/09 , A61K41/00 , A61K45/00 , A61K48/00 , A61P35/00 , A61P43/00 , C12N5/10 , C12N15/87 , C12N15/00
CPC classification number: A61K48/00 , A61K41/0038 , C12N15/87
Abstract: The present invention relates to methods for increasing the efficiency of transformation of cycling cells, the methods comprising synchronizing cells at a first stage of the cell cycle, and transforming the cells at a second stage of the cell cycle within about one cell cycle of the first stage with a genetically engineered nucleic acid that encodes a desired gene product. The invention further relates to cancer therapy and, in particular, to methods of efficiently transforming cancer cells with nucleic acids that encode gene products that inhibit the growth of cancer cells.
Abstract translation: 本发明涉及用于提高循环细胞转化效率的方法，所述方法包括在细胞周期的第一阶段同步细胞，以及在细胞周期的第二阶段，在第一个细胞的约一个细胞周期内转化细胞 具有编码所需基因产物的遗传工程化核酸的阶段。 本发明进一步涉及癌症治疗，尤其涉及用编码抑制癌细胞生长的基因产物的核酸有效转化癌细胞的方法。
-
-
-
-
-
-
-
-
-
Search Results
27
records
(took 0.012 seconds)
